From: Multiple Sclerosis News Today

By: Ana Pena, PHD

 

 

Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports

Prescriptions of two multiple sclerosis (MS) treatments — Merck KGaA‘s Mavenclad (cladribine) and Roche‘s Ocrevus (ocrelizumab) — have been rising in Europe over the past six months, bolstered by greater market access and compassionate use programs, according to a survey of 250 EU neurologists run by Spherix Global Insights…(read more).